Advertisement

NTM Disease Caused by M. kansasii, M. xenopi, M. malmoense, and Other Slowly Growing NTM

  • Theodore K. Marras
  • Sarah K. Brode
Chapter
Part of the Respiratory Medicine book series (RM)

Abstract

Slowly growing NTM are very commonly encountered species in the management of NTM pulmonary disease (NTM-PD) and non-pulmonary infections. With the exception of M. avium complex, this chapter discusses 14 of the more problematic species of this group, providing information to guide the clinician in assessing and managing these infections. The commonly encountered M. kansasii, M. xenopi, and M. malmoense are discussed in greatest detail. Discussions include environmental sources of the organism, common patient phenotypes, typical anatomic sites of infection (pulmonary, non-pulmonary, disseminated), epidemiology, clinical presentation, diagnosis, antimicrobial treatment, and monitoring. Highlighted are areas where there is useful information regarding the role of antimicrobial drug susceptibility testing. Although guideline criteria are considered as the starting point for making a diagnosis of NTM-PD, specifically discussed is the concept that species of varying pathogenicity ought to be assessed with commensurate levels of suspicion. To make appropriate diagnostic and treatment decisions, clinicians must carefully consider what is known about the pathogenicity of the species in addition to all available clinical information. Summary tables present information regarding frequency and anatomic site of disease and antimicrobial treatment recommendations reflecting current guidelines and recent literature.

References

  1. 1.
    Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, et al. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax. 2009;64(6):502–6.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jankovic M, Sabol I, Zmak L, Jankovic VK, Jakopovic M, Obrovac M, et al. Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. The international journal of tuberculosis and lung disease : the official journal of the International Union against. Tuberc Lung Dis. 2016;20(7):934–40.CrossRefGoogle Scholar
  4. 4.
    Morimoto K, Kazumi Y, Shiraishi Y, Yoshiyama T, Murase Y, Ikushima S, et al. Clinical and microbiological features of definite Mycobacterium gordonae pulmonary disease: the establishment of diagnostic criteria for low-virulence mycobacteria. Trans R Soc Trop Med Hyg. 2015;109(9):589–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Braun E, Sprecher H, Davidson S, Kassis I. Epidemiology and clinical significance of non-tuberculous mycobacteria isolated from pulmonary specimens. Int J Tuberc Lung Dis. 2012;17(1):96–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Moon SM, Park HY, Jeon K, Kim SY, Chung MJ, Huh HJ, Ki CS, Lee NY, Shin SJ, Koh WJ. Clinical Significance of Mycobacterium kansasii Isolates from Respiratory Specimens. PLoS One. 2015;10(10):12.CrossRefGoogle Scholar
  7. 7.
    Collins CH, Grange J, Yates MD. Mycobacteria in water. J Appl Bacteriol. 1984;57(2):193–211.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang Y, Mann L, Wilson RW, Brown-Elliott BA, Vincent V, Iinuma Y, Wallace RJ Jr. Molecular analysis of Mycobacterium kansasii isolates from the United States. J Clin Microbiol. 2004;42(1):119–25.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Alcaide F, Richter I, Bernasconi C, Springer B, Hagenau C, Schulze-Röbbecke R, Tortoli E, Martín R, Böttger EC, Telenti A. Heterogeneity and clonality among isolates of Mycobacterium kansasii: implications for epidemiological and pathogenicity studies. J Clin Microbiol. 1997;35(8):6.Google Scholar
  10. 10.
    Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med. 2002;23(3):553–67.CrossRefGoogle Scholar
  12. 12.
    Corbett EL, Hay M, Churchyard GJ, Herselman P, Clayton T, Williams BG, et al. Mycobacterium kansasii and M. scrofulaceum isolates from HIV-negative South African gold miners: incidence, clinical significance and radiology. The international journal of tuberculosis and lung disease : the official journal of the International Union against. Tuberc Lung Dis. 1999;3(6):501–7.Google Scholar
  13. 13.
    Lovell JP, Zerbe C, Olivier KN, Claypool RJ, Frein C, Anderson VL, Freeman AF, Holland SM. Mediastinal and Disseminated Mycobacterium kansasii Disease in GATA2 Deficiency. Ann Am Thorac Soc. 2016;13(12):2169–73.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Veyrier F, Pletzer D, Turenne C, Behr MA. Phylogenetic detection of horizontal gene transfer during the step-wise genesis of Mycobacterium tuberculosis. BMC Evol Biol. 2009;9:196.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L, Bodle EE, et al. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis. 2008;14(3):390–6.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Vesenbeckh S, Wagner S, Mauch H, Roth A, Streubel A, Russmann H, Bauer TT, Matthiessen W, Schonfeld N. Pathogenicity of Mycobacterium kansasii. Pneumologie. 2014;68(8):526–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Jankovic M, Samarzija M, Sabol I, Jakopovic M, Katalinic Jankovic V, Zmak L, Ticac B, Marusic A, Obrovac M, van Ingen J. Geographical distribution and clinical relevance of non-tuberculous mycobacteria in Croatia. Int J Tuberc Lung Dis. 2013;17(6):836–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Ahn CH, Lowell JR, Onstad GD, Shuford EH, Hurst GA. A demographic study of disease due to Mycobacterium kansasii or M intracellulare-avium in Texas. Chest. 1979;75:120–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Shitrit D, Baum G, Priess R, Lavy A, Shitrit AB, Raz M, Shlomi D, Daniele B, Kramer MR. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest. 2006;129(3):771–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Griffith DE, Brown-Elliott B, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis. 2003;37(9):1178–82.PubMedCrossRefGoogle Scholar
  21. 21.
    Rodriguez Diaz JC, López M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. Int J Antimicrob Agents. 2003;21(6):4.CrossRefGoogle Scholar
  22. 22.
    Philley JV, Griffith DE. Treatment of slowly growing mycobacteria. Clin Chest Med. 2015;36(1):79–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Griffith DE. Management of disease due to Mycobacterium kansasii. Clin Chest Med. 2002;23:9.CrossRefGoogle Scholar
  24. 24.
    Pezzia W, Raleigh J, Bailey MC, Toth EA, Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis. 1981;3(5):1035–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Ahn CH, Lowell J, Ahn SS, Ahn S, Hurst GA. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis. 1981;3(5):1028–34.PubMedCrossRefGoogle Scholar
  26. 26.
    Banks J, Hunter A, Campbell IA, Jenkins PA, Smith AP. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax. 1983;38(4):271–4.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Ahn CH, Lowell J, Ahn SS, Ahn SI, Hurst GA. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis. 1983;128(6):1048–50.PubMedGoogle Scholar
  28. 28.
    Santin M, Dorca J, Alcaide F, Gonzalez L, Casas S, Lopez M, Guerra MR. Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. Eur Respir J. 2009;33(1):148–52.PubMedCrossRefGoogle Scholar
  29. 29.
    Sauret J, Hernández-Flix S, Castro E, Hernandez L, Ausina V, Coll P. Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months’ chemotherapy. Tuber Lung Dis. 1995;76(2):104–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Wallace RJ Jr, Dunbar D, Brown BA, Onyi G, Dunlap R, Ahn CH, Murphy DT. Rifampin-resistant Mycobacterium kansasii. Clin Infect Dis. 1994;18(5):736–43.PubMedCrossRefGoogle Scholar
  31. 31.
    Slosarek M, Kubín M, Jaresova M. Water-borne household infections due to Mycobacterium xenopi. Cent Eur J Public Health. 1993;1(2):78–80.PubMedGoogle Scholar
  32. 32.
    Slosarek M, Kubín M, Pokorny J. Water as a possible factor of transmission in mycobacterial infections. Cent Eur J Public Health. 1994;2(2):103–5.PubMedGoogle Scholar
  33. 33.
    Sniadack DH, Ostroff S, Karlix MA, Smithwick RW, Schwartz B, Sprauer MA, Silcox VA, Good RC. A nosocomial pseudo-outbreak of Mycobacterium xenopi due to a contaminated potable water supply: lessons in prevention. Infect Control Hosp Epidemiol. 1993;14(11):636–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Astagneau P, Desplaces N, Vincent V, Chicheportiche V, Botherel A, Maugat S, Lebascle K, Leonard P, Desenclos J, Grosset J, Ziza J, Brucker G. Mycobacterium xenopi spinal infections after discovertebral surgery: investigation and screening of a large outbreak. Lancet. 2001;358(9283):747–51.PubMedCrossRefGoogle Scholar
  35. 35.
    Dailloux M, Abalain ML, Laurain C, Lebrun L, Loos-Ayav C, Lozniewski A, et al. Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients. Eur Respir J. 2006;28:1211–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Del Giudice G, Iadevaia C, Santoro G, Moscariello E, Smeraglia R, Marzo C, et al. Nontuberculous mycobacterial lung disease in patients without HIV infection: a retrospective analysis over 3 years. Clin Respir J. 2011;5(4):203–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19(11):1889–91.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Costrini AM, Mahler D, Gross WM, Hawkins JE, Yesner R, D'Esopo ND. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am Rev Respir Dis. 1981;123(1):104–9.PubMedGoogle Scholar
  39. 39.
    Zenone T, Boibieux A, Tigaud S, Fredenucci JF, Vincent V, Chidiac C, Peyramond D. Non-tuberculous mycobacterial tenosynovitis: a review. Scand J Infect Dis. 1999;31(3):221–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Donnabella V, Salazar-Schicchi J, Bonk S, Hanna B, Rom WN. Increasing incidence of Mycobacterium xenopi at Bellevue Hospital: An emerging pathogen or a product of improved lasboratory methods? Chest. 2000;118:1365–70.PubMedCrossRefGoogle Scholar
  41. 41.
    Marras TK, Chedore P, Jamieson F. Gender and age characteristics of patients with pulmonary nontuberculous mycobateria ata Canadian tertiary-care institution. Am J Respir Crit Care Med. 2008;177:583.Google Scholar
  42. 42.
    Marras TK, Campitelli M, Kwong JC, Lu H, Brode SK, Marchand-Austin A, Gershon AS, Jamieson FB. Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease. Eur Respir J. 2016;48:928–31.PubMedCrossRefGoogle Scholar
  43. 43.
    Carrillo MC, Patsios D, Wagnetz U, Jamieson F, Marras TK. Comparison of the Spectrum of Radiologic and Clinical Manifestations of Pulmonary Disease Caused by Mycobacterium avium Complex and Mycobacterium xenopi. Can Assoc Radiol J. 2014;65(3):207–13.PubMedCrossRefGoogle Scholar
  44. 44.
    Varadi RG, Marras T. Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. Int J Tuberc Lung Dis. 2009;13(10):1210–8.PubMedGoogle Scholar
  45. 45.
    Andrejak C, Thomsen VO, Johansen IS, Riis A, Benfield TL, Duhaut P, et al. Nontuberculous Pulmonary Mycobacteriosis in Denmark: Incidence and Prognostic Factors. Am J Respir Crit Care Med. 2010;181:514–21.PubMedCrossRefGoogle Scholar
  46. 46.
    Marras TK, Campitelli MA, Lu H, Chung H, Brode SK, Marchand-Austin A, et al. Pulmonary nontuberculous mycobacteria–associated deaths, Ontario, Canada, 2001–2013. Emerg Infect Dis [Internet]. 2017. Available from:  https://doi.org/10.3201/eid2303.161927.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Andrejak C, Lescure F, Pukenyte E, Douadi Y, Yazdanpanah Y, Laurans G, Schmit JL, Jounieaux V. Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France. Thorax. 2009;64(4):291–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Hollings NP, Wells AU, Wilson R, Hansell DM. Comparative appearances of non-tuberculous mycobacteria species: a CT study. Eur Radiol. 2002;12(9):2211–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Brown-Elliott BA, Nash K, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev. 2012;25(3):545–82.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax. 2001;56(3):167–72.CrossRefGoogle Scholar
  51. 51.
    Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ, Smith AP. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63(7):627–34.PubMedCrossRefGoogle Scholar
  52. 52.
    Andrejak C, Véziris N, Lescure F-X, Mal H, Bouvry D, Bassinet L, Blanc F-X, Camuset J, Couturaud F, Bervar J-F, Marquette C-H, Thiberville L, Vallerand H, Dalphin J-C, Morel H, Andrejak J, Cadranel J, Jounieaux V. CaMoMy Trial: A Prospective Randomized Clinical Trial to Compare Six-Months Sputum Conversion Rate with a Clarithromycin or Moxifloxacin Containing Regimen in Patients with a M. Xenopi Pulmonary Infection:Â Intermediate Analysis. B49 NON-TUBERCULOUS MYCOBACTERIAL DISEASE AND CASE REPORTS. American Thoracic Society International Conference Abstracts: American Thoracic Society; 2016. p. A3733.Google Scholar
  53. 53.
    Lounis N, Truffot-Pernot C, Bentoucha A, Robert J, Ji B, Grosset J. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimicrob Agents Chemother. 2001;45(11):3229–30.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Andrejak C, Almeida DV, Tyagi S, Converse PJ, Ammerman NC, Grosset JH. Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother. 2016;68(3):659–65.CrossRefGoogle Scholar
  55. 55.
    Parrot RG, Grosset J. Post-surgical outcome of 57 patients with Mycobacterium xenopi pulmonary infection. Tubercle. 1988;69(1):47–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Falkinham JO 3rd. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev. 1996;9(2):177–215.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Hoefsloot W, Boeree MJ, van Ingen J, Bendien S, Magis C, de Lange W, et al. The rising incidence and clinical relevance of Mycobacterium malmoense: a review of the literature. Int J Tuberc Lung Dis. 2008;12(9):987–93.PubMedGoogle Scholar
  58. 58.
    Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604–13.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Buchholz UT, McNeil MM, Keyes LE, Good RC. Mycobacterium malmoense infections in the United States, January 1993 through June 1995. Clin Infect Dis. 1998;27(3):551–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Chocarra A, Gonzalez Lopez A, Breznes MF, Canut A, Rodriguez J, Diego JM. Disseminated infection due to Mycobacterium malmoense in a patient infected with human immunodeficiency virus. Clin Infect Dis. 1994;19(1):203–4.PubMedCrossRefGoogle Scholar
  61. 61.
    Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur Respir J. 2003;21(3):478–82.Google Scholar
  62. 62.
    Hoefsloot W, van Ingen J, de Lange WC, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical relevance of Mycobacterium malmoense isolation in The Netherlands. Eur Respir J. 2009;34(4):926–31.PubMedCrossRefGoogle Scholar
  63. 63.
    Murray MP, Laurenson IF, Hill AT. Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection. Clin Infect Dis. 2008;47(2):222–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Makovcova J, Slany M, Babak V, Slana I, Kralik P. The water environment as a source of potentially pathogenic mycobacteria. J Water Health. 2014;12(2):254–63.PubMedCrossRefGoogle Scholar
  65. 65.
    Thomson RM, Carter R, Tolson C, Coulter C, Huygens F, Hargreaves M. Factors associated with the isolation of Nontuberculous mycobacteria (NTM) from a large municipal water system in Brisbane, Australia. BMC Microbiol. 2013;13:89.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    El Sahly HM, Septimus E, Soini H, Septimus J, Wallace RJ, Pan X, Williams-Bouyer N, Musser JM, Graviss EA. Mycobacterium simiae pseudo-outbreak resulting from a contaminated hospital water supply in Houston, Texas. Clin Infect Dis. 2002;35(7):802–7.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Jordao Junior CM, Lopes F, David S, Farache Filho A, Leite CQ. Detection of nontuberculous mycobacteria from water buffalo raw milk in Brazil. Food Microbiol. 2009;26(6):658–61.PubMedCrossRefGoogle Scholar
  68. 68.
    Shitrit D, Peled N, Bishara J, Priess R, Pitlik S, Samra Z, Kramer MR. Clinical and radiological features of Mycobacterium kansasii infection and Mycobacterium simiae infection. Respir Med. 2008;102(11):1598–603.PubMedCrossRefGoogle Scholar
  69. 69.
    Lavy A, Yoshpe-Purer Y. Isolation of Mycobacterium simiae from clinical specimens in Israel. Tubercle. 1982;63(4):279–85.PubMedCrossRefGoogle Scholar
  70. 70.
    Rynkiewicz DL, Cage G, Butler WR, Ampel NM. Clinical and microbiological assessment of Mycobacterium simiae isolates from a single laboratory in southern Arizona. Clin Infect Dis. 1998;26(3):625–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Valero G, Peters J, Jorgensen JH, Graybill JR. Clinical isolates of Mycobacterium simiae in San Antonio, Texas. An 11-yr review. Am J Respir Crit Care Med. 1995;152(5 Pt 1):1555–7.PubMedCrossRefGoogle Scholar
  72. 72.
    van Ingen J, Boeree M, Dekhuijzen PN, van Soolingen D. Clinical relevance of Mycobacterium simiae in pulmonary samples. Eur Respir J. 2008;31(1):106–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Patel NC, Minifee P, Dishop MK, Munoz FM. Mycobacterium simiae cervical lymphadenitis. Pediatr Infect Dis J. 2007;26(4):362–3.PubMedCrossRefGoogle Scholar
  74. 74.
    van Ingen J, Totten SE, Heifets LB, Boeree MJ, Daley CL. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents. 2012;39(2):173–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Abalain-Colloc ML, Guillerm D, Salaun M, Gouriou S, Vincent V, Picard B. Mycobacterium szulgai isolated from a patient, a tropical fish and aquarium water. Eur J Clin Microbiol Infect Dis. 2003;22(12):768–9.PubMedCrossRefGoogle Scholar
  76. 76.
    van Ingen J, Boeree M, de Lange WC, de Haas PE, Dekhuijzen PN, van Soolingen D. Clinical relevance of Mycobacterium szulgai in The Netherlands. Clin Infect Dis. 2008;46(8):1200–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Yoo H, Jeon K, Kim SY, Jeong BH, Park HY, Ki CS, Lee NY, Shin SJ, Koh WJ. Clinical significance of Mycobacterium szulgai isolates from respiratory specimens. Scandinavica. 2014;46(3):169–74.Google Scholar
  78. 78.
    Benator DA, Kan V, Gordin FM. Mycobacterium szulgai infection of the lung: case report and review of an unusual pathogen. Am J Med Sci. 1997;313(6):346–51.PubMedGoogle Scholar
  79. 79.
    Tortoli E, Besozzi G, Lacchini C, Penati V, Simonetti MT, Emler S. Pulmonary infection due to Mycobacterium szulgai, case report and review of the literature. Eur Respir J. 1998;11(4):975–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Bottger EC, Teske A, Kirschner P, Bost S, Chang HR, Beer V, Hirschel B. Disseminated “Mycobacterium genavense” infection in patients with AIDS. Lancet. 1992;340(8811):76–80.PubMedCrossRefGoogle Scholar
  81. 81.
    Hillebrand-Haverkort ME, Kolk A, Kox LF, Ten Velden JJ, Ten Veen JH. Generalized mycobacterium genavense infection in HIV-infected patients: detection of the mycobacterium in hospital tap water. Scand J Infect Dis. 1999;31(1):63–8.PubMedCrossRefGoogle Scholar
  82. 82.
    van der Wielen PW, Heijnen L, van der Kooij D. Pyrosequence analysis of the hsp65 genes of nontuberculous mycobacterium communities in unchlorinated drinking water in the Netherlands. Appl Environ Microbiol. 2013;79(19):6160–6.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Kiehn TE, Hoefer H, Bottger EC, Ross R, Wong M, Edwards F, Antinoff N, Armstrong D. Mycobacterium genavense infections in pet animals. J Clin Microbiol. 1996;34(7):1840–2.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Portaels F, Realini L, Bauwens L, Hirschel B, Meyers WM, de Meurichy W. Mycobacteriosis caused by Mycobacterium genavense in birds kept in a zoo: 11-year survey. J Clin Microbiol. 1996;34(2):319–23.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Charles P, Lortholary O, Dechartres A, Doustdar F, Viard JP, Lecuit M, Gutierrez MC. Mycobacterium genavense infections: a retrospective multicenter study in France, 1996-2007. Medicine (Baltimore). 2011;90(4):223–30.CrossRefGoogle Scholar
  86. 86.
    Hoefsloot W, van Ingen J, Peters EJ, Magis-Escurra C, Dekhuijzen PN, Boeree MJ, van Soolingen D. Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases. Clin Microbiol Infect. 2012;19(5):432–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Rammaert B, Couderc L, Rivaud E, Honderlick P, Zucman D, Mamzer MF, Cahen P, Bille E, Lecuit M, Lortholary O, Catherinot E. Mycobacterium genavense as a cause of subacute pneumonia in patients with severe cellular immunodeficiency. BMC Infect Dis. 2011;11:311.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Thomsen VO, Dragsted U, Bauer J, Fuurste K, Lundgren J. Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol. 1999;37(12):3901–5.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Siddiqi SH, Laszlo A, Butler WR, Kilburn JO. Bacteriologic investigations of unusual mycobacteria isolated from immunocompromised patients. Diagn Microbiol Infect Dis. 1993;16(4):321–3.PubMedCrossRefGoogle Scholar
  90. 90.
    Prabaker K, Muthiah C, Hayden MK, Weinstein RA, Cheerala J, Scorza ML, et al. Pseudo-outbreak of Mycobacterium gordonae Following the Opening of a newly constructed hospital at a Chicago Medical Center. Infect Control Hosp Epidemiol. 2015;36(2):198–203.PubMedCrossRefGoogle Scholar
  91. 91.
    Arnow PM, Bakir M, Thompson K, Bova JL. Endemic contamination of clinical specimens by Mycobacterium gordonae. Clin Infect Dis. 2000;31(2):472–6.PubMedCrossRefGoogle Scholar
  92. 92.
    Panwalker AP, Fuhse E. Nosocomial Mycobacterium gordonae pseudoinfection from contaminated ice machines. Infect Control. 1986;7(2):67–70.PubMedCrossRefGoogle Scholar
  93. 93.
    Stine TM, Harris AA, Levin S, Rivera N, Kaplan RL. A pseudoepidemic due to atypical mycobacteria in a hospital water supply. JAMA. 1987;258(6):809–11.PubMedCrossRefGoogle Scholar
  94. 94.
    Tokars JI, McNeil MM, Tablan OC, Chapin-Robertson K, Patterson JE, Edberg SC, et al. Mycobacterium gordonae pseudoinfection associated with a contaminated antimicrobial solution. J Clin Microbiol. 1990;28(12):2765–9.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Steere AC, Corrales J, von Graevenitz A. A cluster of Mycobacterium gordonae isolates from bronchoscopy specimens. Am Rev Respir Dis. 1979;120(1):214–6.PubMedGoogle Scholar
  96. 96.
    Gubler JG, Salfinger M, von Graevenitz A. Pseudoepidemic of nontuberculous mycobacteria due to a contaminated bronchoscope cleaning machine. Report of an outbreak and review of the literature. Chest. 1992;101(5):1245–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Metchock B, Nolte F, Wallace RJ Jr. In: Murray P, editor. Mycobacterium. Washington, D.C.: ASM Press; 1999.Google Scholar
  98. 98.
    Aguado JM, Gomez-Garces JL, Manrique A, Soriano F. Pulmonary infection by Mycobacterium gordonae in an immunocompromised patient. Diagn Microbiol Infect Dis. 1987;7(4):261–3.PubMedCrossRefGoogle Scholar
  99. 99.
    Youssef D, Shams WE, Elshenawy Y, El-Abbassi A, Moorman JP. Pulmonary infection with caseating mediastinal lymphadenitis caused by Mycobacterium gordonae. Int J Mycobacteriol. 2014;3(3):220–3.PubMedCrossRefGoogle Scholar
  100. 100.
    Nanda Kumar U, Varkey B. Pulmonary infection caused by Mycobacterium gordonae. Br J Dis Chest. 1980;74(2):189–92.PubMedCrossRefGoogle Scholar
  101. 101.
    Harro C, Braden GL, Morris AB, Lipkowitz GS, Madden RL. Failure to cure Mycobacterium gordonae peritonitis associated with continuous ambulatory peritoneal dialysis. Clin Infect Dis. 1997;24(5):955–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Rusconi S, Gori A, Vago L, Marchetti G, Franzetti F. Cutaneous infection caused by Mycobacterium gordonae in a human immunodeficiency virus-infected patient receiving antimycobacterial treatment. Clin Infect Dis. 1997;25(6):1490–1.PubMedCrossRefGoogle Scholar
  103. 103.
    Hirohama D, Ishibashi Y, Kawarazaki H, Kume H, Fujita T. Successful treatment of Mycobacterium gordonae exit-site and tunnel infection by partial catheter reimplantation of the Tenckhoff catheter. Perit Dial Int. 2011;31(3):368–70.PubMedCrossRefGoogle Scholar
  104. 104.
    Weinberger M, Berg SL, Feuerstein IM, Pizzo PA, Witebsky FG. Disseminated infection with Mycobacterium gordonae: report of a case and critical review of the literature. Clin Infect Dis. 1992;14(6):1229–39.PubMedCrossRefGoogle Scholar
  105. 105.
    Bonnet E, Massip P, Bauriaud R, Alric L, Auvergnat JC. Disseminated Mycobacterium gordonae infection in a patient infected with human immunodeficiency virus. Clin Infect Dis. 1996;23(3):644–5.PubMedCrossRefGoogle Scholar
  106. 106.
    Asija A, Prasad A, Eskridge E. Disseminated Mycobacterium gordonae infection in an immunocompetent host. Am J Ther. 2011;18(3):e75–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Marchevsky A, Damsker B, Gribetz A, Tepper S, Geller SA. The spectrum of pathology of nontuberculous mycobacterial infections in open-lung biopsy specimens. Am J Clin Pathol. 1982;78(5):695–700.PubMedCrossRefGoogle Scholar
  108. 108.
    Mazumder SA, Hicks A, Norwood J. Mycobacterium gordonae pulmonary infection in an immunocompetent adult. N Am J Med Sci. 2010;2(4):205–7.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Brown BA, Wallace RJ Jr, Onyi GO. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother. 1992;36(9):1987–90.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Rastogi N, Goh KS, Guillou N, Labrousse V. Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs? Zentralbl Bakteriol. 1992;277(4):474–84.PubMedCrossRefGoogle Scholar
  111. 111.
    Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, Prins JM, Kuijper EJ. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev. 2011;24(4):701–17.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Falkinham JO 3rd, Norton CD, LeChevallier MW. Factors influencing numbers of Mycobacterium avium, Mycobacterium intracellulare, and other Mycobacteria in drinking water distribution systems. Appl Environ Microbiol. 2001;67(3):1225–31.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Dawson DJ, Jennis F. Mycobacteria with a growth requirement for ferric ammonium citrate, identified as Mycobacterium haemophilum. J Clin Microbiol. 1980;11(2):190–2.PubMedPubMedCentralGoogle Scholar
  114. 114.
    Samra Z, Kaufmann L, Zeharia A, Ashkenazi S, Amir J, Bahar J, et al. Optimal detection and identification of Mycobacterium haemophilum in specimens from pediatric patients with cervical lymphadenopathy. J Clin Microbiol. 1999;37(3):832–4.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Lindeboom JA, Prins JM, Bruijnesteijn van Coppenraet ES, Lindeboom R, Kuijper EJ. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum. Clin Infect Dis. 2005;41(11):1569–75.PubMedCrossRefGoogle Scholar
  116. 116.
    Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, Samra Z, Kaufman L, Amir J. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J. 2008;27(10):920–2.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Giulieri S, Morisod B, Edney T, Odman M, Genne D, Malinverni R, et al. Outbreak of Mycobacterium haemophilum infections after permanent makeup of the eyebrows. Clin Infect Dis. 2011;52(4):488–91.PubMedCrossRefGoogle Scholar
  118. 118.
    Shah MK, Sebti A, Kiehn TE, Massarella SA, Sepkowitz KA. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis. 2001;33(3):330–7.PubMedCrossRefGoogle Scholar
  119. 119.
    Kiehn TE, White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis. 1994;13(11):925–31.PubMedCrossRefGoogle Scholar
  120. 120.
    McBride ME, Rudolph AH, Tschen JA, Cernoch P, Davis J, Brown BA, et al. Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol. 1991;127(2):276–7.PubMedCrossRefGoogle Scholar
  121. 121.
    Cross GB, Le Q, Webb B, Jenkin GA, Korman TM, Francis M, et al. Mycobacterium haemophilum bone and joint infection in HIV/AIDS: case report and literature review. Int J STD AIDS. 2015;26(13):974–81.PubMedCrossRefGoogle Scholar
  122. 122.
    Torvinen E, Suomalainen S, Paulin L, Kusnetsov J. Mycobacteria in Finnish cooling tower waters. APMIS. 2013;122(4):353–8.PubMedCrossRefGoogle Scholar
  123. 123.
    Marshall HM, Carter R, Torbey MJ, Minion S, Tolson C, Sidjabat HE, Huygens F, Hargreaves M, Thomson RM. Mycobacterium lentiflavum in drinking water supplies, Australia. Emerg Infect Dis. 2011;17(3):395–402.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Tortoli E, Bartoloni A, Erba ML, Levre E, Lombardi N, Mantella A, Mecocci L. Human infections due to Mycobacterium lentiflavum. J Clin Microbiol. 2002;40(2):728–9.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Neonakis IK, Gitti Z, Kourbeti IS, Michelaki H, Baritaki M, Alevraki G, Papadomanolaki E, Tsafaraki E, Tsouri A, Baritaki S, Krambovitis E, Spandidos DA. Mycobacterial species diversity at a general hospital on the island of Crete: first detection of Mycobacterium lentiflavum in Greece. Scand J Infect Dis. 2007;39(10):875–9.PubMedCrossRefGoogle Scholar
  126. 126.
    Safdar A, Han X. Mycobacterium lentiflavum, a recently identified slow-growing mycobacterial species: clinical significance in immunosuppressed cancer patients and summary of reported cases of infection. Eur J Clin Microbiol Infect Dis. 2005;24(8):554–8.PubMedCrossRefGoogle Scholar
  127. 127.
    Jeong BH, Song J, Kim W, Han SG, Ko Y, Song J, Chang B, Hong G, Kim SY, Choi GE, Shin SJ, Koh WJ. Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium lentiflavum in a Patient with Bronchiectasis. Tuberc Respir Dis (Seoul). 2013;74(4):187–90.CrossRefGoogle Scholar
  128. 128.
    Lee YC, Kim S, Gang SJ, Park SY, Kim SR. Acute necrotizing pneumonia combined with parapneumonic effusion caused by Mycobacterium lentiflavum: a case report. BMC Infect Dis. 2015;15:354.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Phelippeau M, Dubus J, Reynaud-Gaubert M, Gomez C, Stremler le Bel N, Bedotto M, Prudent E, Drancourt M. Prevalence of Mycobacterium lentiflavum in cystic fibrosis patients, France. BMC Pulm Med. 2015;15:131.PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Molteni C, Gazzola L, Cesari M, Lombardi A, Salerno F, Tortoli E, Codecasa L, Penati V, Franzetti F, Gori A. Mycobacterium lentiflavum infection in immunocompetent patient. Emerg Infect Dis. 2005;11(1):119–22.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Jimenez-Montero B, Baquero-Artigao F, Saavedra-Lozano J, Tagarro-Garcia A, Blazquez-Gamero D, Cilleruelo-Ortega MJ, Ramos-Amador JT, Gale-Anso I, Marin N, Gomez-Garcia R, Santiago-Garcia B, Garrido J, Lopez G. Comparison of Mycobacterium lentiflavum and Mycobacterium avium-intracellulare complex lymphadenitis. Pediatr Infect Dis J. 2014;33(1):28–34.PubMedCrossRefGoogle Scholar
  132. 132.
    Johnson MG, Stout JE. Twenty-eight cases of Mycobacterium marinum infection: retrospective case series and literature review. Infection. 2015;43(6):655–62.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Aubry A, Chosidow O, Caumes E, Robert J, Cambau E. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med. 2002;162(15):1746–52.PubMedCrossRefGoogle Scholar
  134. 134.
    Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis. 2003;37(3):390–7.PubMedCrossRefGoogle Scholar
  135. 135.
    Colville A. Retrospective review of culture-positive mycobacterial lymphadenitis cases in children in Nottingham, 1979-1990. Eur J Clin Microbiol Infect Dis. 1993;12(3):192–5.PubMedCrossRefGoogle Scholar
  136. 136.
    Jacobs S, George A, Papanicolaou GA, Lacouture ME, Tan BH, Jakubowski AA, et al. Disseminated Mycobacterium marinum infection in a hematopoietic stem cell transplant recipient. Transpl Infect Dis. 2012;14(4):410–4.PubMedCrossRefGoogle Scholar
  137. 137.
    Tchornobay AM, Claudy AL, Perrot JL, Levigne V, Denis M. Fatal disseminated Mycobacterium marinum infection. Int J Dermatol. 1992;31(4):286–7.PubMedCrossRefGoogle Scholar
  138. 138.
    Asakura T, Ishii M, Kikuchi T, Kameyama K, Namkoong H, Nakata N, et al. Disseminated Mycobacterium marinum Infection With a Destructive Nasal Lesion Mimicking Extranodal NK/T Cell Lymphoma: A Case Report. Medicine. 2016;95(11):e3131.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Danko JR, Gilliland WR, Miller RS, Decker CF. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis. 2009;41(4):252–5.PubMedCrossRefGoogle Scholar
  140. 140.
    Lai CC, Lee LN, Chang YL, Lee YC, Ding LW, Hsueh PR. Pulmonary infection due to Mycobacterium marinum in an immunocompetent patient. Clin Infect Dis. 2005;40(1):206–8.PubMedCrossRefGoogle Scholar
  141. 141.
    Velu PP, Fernandes SE, Laurenson IF, Noble DD. Pulmonary Mycobacterium marinum infection: ‘fish tank granuloma’ of the lung. Scott Med J. 2016;61(4):203–6.PubMedCrossRefGoogle Scholar
  142. 142.
    Feng Y, Xu H, Wang H, Zhang C, Zong W, Wu Q. Outbreak of a cutaneous Mycobacterium marinum infection in Jiangsu Haian, China. Diagn Microbiol Infect Dis. 2011;71(3):267–72.PubMedCrossRefGoogle Scholar
  143. 143.
    Eberst E, Dereure O, Guillot B, Trento C, Terru D, van de Perre P, et al. Epidemiological, clinical, and therapeutic pattern of Mycobacterium marinum infection: a retrospective series of 35 cases from southern France. J Am Acad Dermatol. 2012;66(1):e15–6.PubMedCrossRefGoogle Scholar
  144. 144.
    Abbas O, Marrouch N, Kattar MM, Zeynoun S, Kibbi AG, Rached RA, et al. Cutaneous non-tuberculous Mycobacterial infections: a clinical and histopathological study of 17 cases from Lebanon. J Eur Acad Dermatol Venereol. 2011;25(1):33–42.PubMedCrossRefGoogle Scholar
  145. 145.
    Wolinsky E, Gomez F, Zimpfer F. Sporotrichoid Mycobacterium marinum infection treated with rifampin-ethambutol. Am Rev Respir Dis. 1972;105(6):964–7.PubMedGoogle Scholar
  146. 146.
    von Reyn CF, Waddell RD, Eaton T, Arbeit RD, Maslow JN, Barber TW, et al. Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire and Kenya. J Clin Microbiol. 1993;31(12):3227–30.Google Scholar
  147. 147.
    Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis. 1995;20(4):954–63.PubMedCrossRefGoogle Scholar
  148. 148.
    Suzuki S, Morino E, Ishii M, Namkoong H, Yagi K, Asakura T, et al. Clinical characteristics of pulmonary Mycobacterium scrofulaceum disease in 2001-2011: A case series and literature review. J Infect Chemother. 2016;22(9):611–6.PubMedCrossRefGoogle Scholar
  149. 149.
    Ito A, Yoshida Y, Higaki-Mori H, Watanabe T, Nakanaga K, Ishii N, et al. Multiple skin lesions caused by Mycobacterium scrofulaceum infection. Eur J Dermatol. 2011;21(6):1014–5.PubMedGoogle Scholar
  150. 150.
    Lai J, Abbey BV, Jakubovic HR. Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. Am J Dermatopathol. 2013;35(2):266–9.PubMedCrossRefGoogle Scholar
  151. 151.
    Carter TI, Frelinghuysen P, Daluiski A, Brause BD, Wolfe SW. Flexor tenosynovitis caused by Mycobacterium scrofulaceum: case report. J Hand Surg. 2006;31(8):1292–5.CrossRefGoogle Scholar
  152. 152.
    Phoa LL, Khong KS, Thamboo TP, Lam KN. A case of Mycobacterium scrofulaceum osteomyelitis of the right wrist. Ann Acad Med Singap. 2000;29(5):678–81.PubMedGoogle Scholar
  153. 153.
    Sanders JW, Walsh AD, Snider RL, Sahn EE. Disseminated Mycobacterium scrofulaceum infection: a potentially treatable complication of AIDS. Clin Infect Dis. 1995;20(3):549.PubMedCrossRefGoogle Scholar
  154. 154.
    Jang HS, Jo JH, Oh CK, Kim MB, Lee JB, Chang CL, et al. Successful treatment of localized cutaneous infection caused by Mycobacterium scrofulaceum with clarithromycin. Pediatr Dermatol. 2005;22(5):476–9.PubMedCrossRefGoogle Scholar
  155. 155.
    Mayall B, Gurtler V, Irving L, Marzec A, Leslie D. Identification of Mycobacterium shimoidei by molecular techniques: case report and summary of the literature. Int J Tuberc Lung Dis. 1999;3(2):169–73.PubMedGoogle Scholar
  156. 156.
    Galizzi N, Tortoli E, Gori A, Morini F, Lapadula G. A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome. J Clin Microbiol. 2013;51(10):3467–8.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Furrer H, Bodmer T, von Overbeck J. Disseminated nontuberculous mycobacterial infections in AIDS patients. Schweiz Med Wochenschr. 1994;124(3):89–96.PubMedGoogle Scholar
  158. 158.
    Baird TM, Carter R, Eather G, Thomson R. Mycobacterium shimoidei, a Rare Pulmonary Pathogen, Queensland, Australia. Emerg Infect Dis. 2017;23(11):1919–1922.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Kanaji N, Kushida Y, Bandoh S, Ishii T, Haba R, Tadokoro A, Watanabe N, Takahama T, Kita N, Dobashi H, Matsunaga T. Membranous glomerulonephritis associated with Mycobacterium shimoidei pulmonary infection. Am J Case Rep. 2013;14:543–7.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Saito H, Zayasu K, Shigeto E, Iwamoto T, Nakanaga K, Kodama A, Ishii N. Two cases of lung infection due to Mycobacterium shimoidei, with special reference to bacteriological investigation. Kansenshogaku Zasshi. 2007;81(1):12–9.PubMedCrossRefGoogle Scholar
  161. 161.
    Takayama S, Tominaga S, Tsukada Y, Ohkochi M, Inase N. A case of pulmonary Mycobacterium shimoidei infection. Kekkaku. 2006;81(8):537–41.PubMedGoogle Scholar
  162. 162.
    Vasireddy R, Vasireddy S, Brown-Elliott BA, Wengenack NL, Eke UA, Benwill JL, et al. Mycobacterium arupense, Mycobacterium heraklionense, and a Newly Proposed Species, "Mycobacterium virginiense" sp. nov., but Not Mycobacterium nonchromogenicum, as Species of the Mycobacterium terrae Complex Causing Tenosynovitis and Osteomyelitis. J Clin Microbiol. 2016;54(5):1340–51.PubMedPubMedCentralCrossRefGoogle Scholar
  163. 163.
    Tortoli E, Gitti Z, Klenk HP, Lauria S, Mannino R, Mantegani P, et al. Survey of 150 strains belonging to the Mycobacterium terrae complex and description of Mycobacterium engbaekii sp. nov., Mycobacterium heraklionense sp. nov. and Mycobacterium longobardum sp. nov. Int J Syst Evol Microbiol. 2013;63(Pt 2):401–11.PubMedCrossRefGoogle Scholar
  164. 164.
    Lockwood WW, Friedman C, Bus N, Pierson C, Gaynes R. An outbreak of Mycobacterium terrae in clinical specimens associated with a hospital potable water supply. Am Rev Respir Dis. 1989;140(6):1614–7.PubMedCrossRefGoogle Scholar
  165. 165.
    Smith DS, Lindholm-Levy P, Huitt GA, Heifets LB, Cook JL. Mycobacterium terrae: case reports, literature review, and in vitro antibiotic susceptibility testing. Clin Infect Dis. 2000;30(3):444–53.PubMedCrossRefGoogle Scholar
  166. 166.
    Spence TH, Ferris VM. Spontaneous resolution of a lung mass due to infection with Mycobacterium terrae. South Med J. 1996;89(4):414–6.PubMedCrossRefGoogle Scholar
  167. 167.
    Peters EJ, Morice R. Miliary pulmonary infection caused by Mycobacterium terrae in an autologous bone marrow transplant patient. Chest. 1991;100(5):1449–50.PubMedCrossRefGoogle Scholar
  168. 168.
    Tonner JA, Hammond MD. Pulmonary disease caused by Mycobacterium terrae complex. South Med J. 1989;82(10):1279–82.PubMedCrossRefGoogle Scholar
  169. 169.
    Palmero DJ, Teres RI, Eiguchi K. Pulmonary disease due to Mycobacterium terrae. Tubercle. 1989;70(4):301–3.PubMedCrossRefGoogle Scholar
  170. 170.
    Krisher KK, Kallay MC, Nolte FS. Primary pulmonary infection caused by Mycobacterium terrae complex. Diagn Microbiol Infect Dis. 1988;11(3):171–5.PubMedCrossRefGoogle Scholar
  171. 171.
    Kuze F, Mitsuoka A, Chiba W, Shimizu Y, Ito M, Teramatsu T, et al. Chronic pulmonary infection caused by Mycobacterium terrae complex: a resected case. Am Rev Respir Dis. 1983;128(3):561–5.PubMedCrossRefGoogle Scholar
  172. 172.
    Tsukamura M, Kita N, Otsuka W, Shimoide H. A study of the taxonomy of the Mycobacterium nonchromogenicum complex and report of six cases of lung infection due to Mycobacterium nonchromogenicum. Microbiol Immunol. 1983;27(3):219–36.PubMedCrossRefGoogle Scholar
  173. 173.
    Chan TH, Ng KC, Ho A, Scheel O, Lai CK, Leung R. Urinary tract infection caused by Mycobacterium terrae complex. Tuber Lung Dis. 1996;77(6):555–7.PubMedCrossRefGoogle Scholar
  174. 174.
    Fujisawa K, Watanabe H, Yamamoto K, Nasu T, Kitahara Y, Nakano M. Primary atypical mycobacteriosis of the intestine: a report of three cases. Gut. 1989;30(4):541–5.PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Shimizu T, Furumoto H, Takahashi T, Yasuno H, Muto M. Lymphadenitis due to Mycobacterium terrae in an immunocompetent patient. Dermatology (Basel, Switz). 1999;198(1):97–8.CrossRefGoogle Scholar
  176. 176.
    Carbonara S, Tortoli E, Costa D, Monno L, Fiorentino G, Grimaldi A, et al. Disseminated Mycobacterium terrae infection in a patient with advanced human immunodeficiency virus disease. Clin Infect Dis. 2000;30(5):831–5.PubMedCrossRefGoogle Scholar
  177. 177.
    van der Werf TS, Stinear T, Stienstra Y, van der Graaf WT, Small PL. Mycolactones and Mycobacterium ulcerans disease. Lancet (Lond Engl). 2003;362(9389):1062–4.CrossRefGoogle Scholar
  178. 178.
    van der Werf TS, van der Graaf WT, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet (Lond Engl). 1999;354(9183):1013–8.CrossRefGoogle Scholar
  179. 179.
    Sugawara M, Ishii N, Nakanaga K, Suzuki K, Umebayashi Y, Makigami K, et al. Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan. J Dermatol. 2015;42(6):588–95.PubMedCrossRefGoogle Scholar
  180. 180.
    Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Scott JT, et al. Mycobacterium ulcerans disease: role of age and gender in incidence and morbidity. Tropical Med Int Health. 2004;9(12):1297–304.CrossRefGoogle Scholar
  181. 181.
    Raghunathan PL, Whitney EA, Asamoa K, Stienstra Y, Taylor TH Jr, Amofah GK, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis. 2005;40(10):1445–53.PubMedCrossRefGoogle Scholar
  182. 182.
    Bratschi MW, Ruf MT, Andreoli A, Minyem JC, Kerber S, Wantong FG, et al. Mycobacterium ulcerans persistence at a village water source of Buruli ulcer patients. PLoS Negl Trop Dis. 2014;8(3):e2756.PubMedPubMedCentralCrossRefGoogle Scholar
  183. 183.
    Herbinger KH, Adjei O, Awua-Boateng NY, Nienhuis WA, Kunaa L, Siegmund V, et al. Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect Dis. 2009;48(8):1055–64.PubMedCrossRefGoogle Scholar
  184. 184.
    World Health Organization. Treatment of Mycobacterium ulcerans disease (Buruli ulcer): guidance for health workers. WHO Press. Geneva, Switzerland. 2012.Google Scholar
  185. 185.
    Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, et al. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet (Lond, Engl). 2010;375(9715):664–72.CrossRefGoogle Scholar
  186. 186.
    Chauty A, Ardant MF, Marsollier L, Pluschke G, Landier J, Adeye A, et al. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis. 2011;52(1):94–6.PubMedCrossRefGoogle Scholar
  187. 187.
    Converse PJ, Nuermberger EL, Almeida DV, Grosset JH. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol. 2011;6(10):1185–98.PubMedPubMedCentralCrossRefGoogle Scholar
  188. 188.
    Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU, et al. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Tropical Med Int Health. 2005;10(12):1251–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Respirology, Department of MedicineToronto Western Hospital, University Health Network, University of TorontoTorontoCanada
  2. 2.Division of Respirology, Department of MedicineToronto Western Hospital, University Health Network and West Park Healthcare Centre, University of TorontoTorontoCanada

Personalised recommendations